CSAAI 2017 A Midsummer Night's Wheeze

Huntington Beach, CA US
June 30, 2017 to July 2, 2017

This program will bring the participant up-to-date on the latest research on preventing allergic illnesses through modification of the microbiome, to use of allergens to modify the immune system (SCIT/SLIT/OIT) to biologics, as well as understand through review and update the immune dysregulation leading to primary immunodeficiencies. 

Accreditation 
This 
activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and California Society of Allergy, Asthma & Immunology (CSAAI) .  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The 
American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  


Commercial Support
This activity is supported by independent education grants from CSL Behring, Greer, Sanofi

Target Audience

Practicing allergists, primary care physicians and allied healthcare providers in the field of allergy and immunology.

Learning Objectives

At the conclusion of this activity, participants should be able to:

-       Summarize recent advances in understanding how the respiratory microbiome influences asthma and COPD and the factors that influence the respiratory microbiome

-       Describe the interactions between therapeutics and the respiratory microbiome and this effect on treatment outcome

-       Describe recent advances in understanding how the skin microbiome influences eczema and other allergic skin diseases

-       Describe recent treatment modalities for eczema and particularly severe eczema and the effect of modulation of the microbiome 

-       Describe the effect of air pollutants on the immune system and the impact on asthma and respiratory allergy 

-       Diagnose and manage exercise anaphylaxis and asthma

-       Summarize the recent advances in knowledge of how exposure to oral allergens change the immune system toward tolerance and desensitization and describe the current recommendations and controversial issues

-       Summarize recent advances in biologics in the treatment of asthma, including indications and contraindications, modulation of the immune system (cytokine/pathophysiologic changes) with administration, and relevant biologics in the US healthcare market

-       Summarize recent advances in biologics in the treatment of allergic skin diseases, including indications and contraindications, modulation of the immune system (cytokine/pathophysiologic changes) with administration, and relevant biologics in the US healthcare market

-       Describe recent advances in newly described primary immunodeficiencies (many presenting with CVID-like clinical pictures plus autoimmunity and others with more autoimmunity), and new targeted therapies in the treatment/potential treatment of these diseases

-       Describe basic testing for primary immunodeficiencies, as well as describe the recent advances in testing and genomic testing

Additional information
Disclosure: 

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

James Baker, MD - Speaker

Principal Investigator – Aimmune Therapeutics, Inc., Amgen, AstraZeneca, Biocryst, Circassia, CSL Behring, Dyax, GlaxoSmithKline, Merck, Mylan, Optinose, Pearl, Pharming, Sanofi-Aventis, Shire, Stallergens, Teva

Spouse – Maruho Co. Ltd, Novartis, Pfizer, Prominus Pharma, Regeneron, Watson Laboratories

Jonathan Corren, MD – Speaker

Consultant – Genentech, Regeneron

Advisory committee member – Genentech, Sanofi, Teva, Novartis

Thomas A. Fleisher, MD, FAAAAI, FACAAI – Speaker

Co-editor – Elsevier: Clinical Immunology: Principles and Practice 4th ed

Donald Y. M. Leung, MD, PhD – Speaker

Consultant – Sanofi Genzyme,  Regeneron

Contracted Research – Medimmune

James L. Sublett, MD, FACAAI – Speaker

Board member – AllergyZone,

Speaker/Teacher – Genentech, Boston Scientific, Circassia, Meda, Kaleo

Advisory Committee member – AstraZeneca

Robert Eitches, MD – Planner

Speaker – Merck

Marilyn Li, MD – Planner

Speaker – Meda

Travis Miller, MD – Planner

Speaker – AstraZeneca, Genentech, Meda, Mylan

Advisory Board – Meda, Kaleo

Research – Teva

Madeline Ramos, MD – Planner

Speaker – Teva

Raffi Tachdjian, MD – Planner

Speaker – CSL Behring, Shire, Pharming, Alcon, Teva, Mylan

Advisory – CSL Behring, Shire, Teva

Research Grant – Shire

The following have no relevant financial relationships to disclose:

Yvonne Huang, MD – Speaker

Tiffany Jean, MD – Speaker

Sheila Bonilla, MD, MS – Presenter, Planner

Christina Schwindt, MD – Presenter, Planner, Reviewer

Karol Anderson – Planner

Vinay Gowda, MD – Planner

Vincent Tubiolo, MD – Planner

Course summary
Available credit: 
  • 10.25 AMA PRA Category 1 Credit™
  • 10.25 Attendance
Course opens: 
06/30/2017
Course expires: 
07/02/2019
Event starts: 
06/30/2017 - 12:00pm
Event ends: 
07/02/2017 - 12:00pm
Cost:
$0.00
Rating: 
0
Hyatt Regency Convention Center
21500 Pacific Coast Highway
Huntington Beach, CA 92648
United States

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Greater Kansas City Allergy Society (GKCAS). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 10.25AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Funding

This activity is supported by independent education grants from CSL Behring, Greer, Sanofi

Available Credit

  • 10.25 AMA PRA Category 1 Credit™
  • 10.25 Attendance

Accreditation Period

Course opens: 
06/30/2017
Course expires: 
07/02/2019

Price

Cost:
$0.00
Please login or create an account to take this course.